FRANKLIN LAKES, N.J., May 28, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced plans to initiate a patient data ...
The US Food and Drug Administration is alerting the public of a potentially high-risk device issue related to Rotarex Atherectomy Systems (Bard Peripheral Vascular) used in peripheral artery ...
Becton, Dickinson and Company (BD) is set to initiate a multi-centre registry study, XTRACT, of the Rotarex Atherectomy System, aimed at measuring real-world outcomes for individuals with peripheral ...
The FDA is getting the word out on a high-risk issue related to artery-clearing catheters from BD’s Bard Peripheral Vascular division. According to the agency, BD has reported 30 serious injuries and ...
Becton, Dickinson and Company BDX, popularly known as BD, announced the enrollment of the first patient in the XTRACT Registry. It is a prospective, multi-center, single-arm, post-market registry ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results